Market Place
Sourcing Support
Bristol Myers Squibb Showcases Cardiovascular Data at AHA 2024
11 Nov 2024 //
BUSINESSWIRE
Edgewise Stock Up 50% On Heart Disease Drug Data
19 Sep 2024 //
FIERCE BIOTECH
Long-Term Data Confirms CAMZYOS® Efficacy In Symptomatic oHCM Patients
01 Sep 2024 //
BUSINESSWIRE
Bristol Myers Squibb To Present Cardiovascular Data At ECS 2024
27 Aug 2024 //
INDIANPHARMAPOST
Cytokinetics looks to take on BMS’ Camzyos in hypertrophic cardiomyopathy
15 May 2024 //
CLINICALTRIALSARENA
Cytokinetics shows hand in high stakes rivalry with BMS` Camzyos
13 May 2024 //
FIERCE BIOTECH
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten
24 Oct 2023 //
GLOBENEWSWIRE
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten
28 Aug 2023 //
GLOBENEWSWIRE
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten)
28 Aug 2023 //
BUSINESSWIRE
BMS` Camzyos (mavacamten) Receives Approval in Europe
07 Aug 2023 //
EMA
Bristol Myers Squibb`s Camzyos (mavacamten) Receives Approval in Europe
24 Jul 2023 //
EMA
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS
27 Jun 2023 //
FINANCE YAHOO
USFDA of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS®
15 Jun 2023 //
BUSINESSWIRE
Bristol`s Camyzos picks up early nod from England`s NICE
03 Jun 2023 //
FIERCE PHARMA
LianBio Announces Marketing Approval of CAMZYOS in the Macau SAR of China
11 May 2023 //
GLOBENEWSWIRE
BMS Receives Positive CHMP Opinion Recommending Approval for CAMZYOS®
26 Apr 2023 //
BUSINESSWIRE
LianBio Announces (NMPA) Acceptance Priority Review of NDA for Mavacamten
21 Apr 2023 //
GLOBENEWSWIRE
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio
02 Nov 2022 //
BUSINESSWIRE
BMS lines up a date with the FDA to expand the footprint of its $13B heart drug
22 Oct 2022 //
ENDPTS
U.S.FDA Accepts Supplemental New Drug Application for CAMZYOS (mavacamten)
21 Oct 2022 //
BUSINESSWIRE
LianBio completes enrollment in phase 3 EXPLORER-CN trial
12 Aug 2022 //
PHARMABIZ
LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten
10 Aug 2022 //
GLOBENEWSWIRE
U.S. FDA Approves Camzyos (mavacamten) for HCM
29 Apr 2022 //
GLOBENEWSWIRE
BMS wins FDA approval of $13B cardio drug mavacamten
29 Apr 2022 //
BIOPHARMADIVE
Bristol Myers touts upbeat data for its blockbuster heart drug candidate
05 Apr 2022 //
ENDPTS
Mavacamten: Reduction in Need for Septal Reduction Therapy in Phase 3 Trial
02 Apr 2022 //
BUSINESSWIRE
Bristol Myers uncorks more winning data for blockbuster-potential heart drug
16 Feb 2022 //
ENDPTS
LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China
15 Feb 2022 //
GLOBENEWSWIRE
LianBio Begins Dosing in Phase 3 Trial of Mavacamten in OHC
10 Jan 2022 //
GLOBENEWSWIRE
US FDA extends review of BMS’ NDA for mavacamten to treat symptomatic oHCM
22 Nov 2021 //
PHARMABIZ
FDA delays its decision on Bristol Myers` $13B heart drug another three months
20 Nov 2021 //
ENDPTS
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
19 Nov 2021 //
BUSINESSWIRE
NBA rookie talks about his heart diagnosis in new BMS campaign
15 Nov 2021 //
FIERCEPHARMA
BMS` $13B MyoKardia heart drug gets along with beta blockers
13 Nov 2021 //
FIERCEBIOTECH
A couple months ahead of PDUFA data, BMS rolls out long-term data for mavacamten
13 Nov 2021 //
ENDPTS
ICER Publishes Evidence Report on Mavacamten for Hypertrophic Cardiomyopathy
07 Oct 2021 //
ICER
EMA Validates BMS’ MAA of Mavacamten for Obstructive Hypertrophic Cardiomyopathy
01 Oct 2021 //
BIOSPACE
EXPLORER-HCM Trial finds substantial health status improvements with mavacamten
20 May 2021 //
PRWEB
MyoKardia Announces Primary and All Secondary Endpoints Met in Ph3 Mavacamten
11 May 2020 //
GLOBENEWSWIRE
Sanofi walks away from MyoKardia heart drug partnership
04 Jan 2019 //
ENDPTS
